South Africa to more than double ARV access
The South African government has announced plans to increase to 1.4 million the number of people receiving antiretroviral drug treatment over the next three years, part of a program estimated to cost about $90.0 million. The country has the largest number of HIV/AIDS cases worldwide, believed to stand at five million.
Trevor Manuel, the Minister of Finance, included the measures in a budget speech to South Africa's Parliament. He said: "our [ARV] program now covers 630,000 people and the medium-term expenditure framework provides for an increase to 1.4 million by 2011-2012." Mr Manuel also outlined proposals to introduce new pneumoccocal pneumonia and rotavirus vaccines for pediatric use, the Agence France Presse reports.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze